Alnylam Pharmaceuticals
ALNY
$286.98
-2.20%
Alnylam Pharmaceuticals is a biotechnology company and a pioneer in the development of RNA interference (RNAi) therapeutics, a platform for silencing disease-causing genes. It is the clear commercial leader in this field, with a portfolio of approved treatments for rare genetic diseases like hATTR amyloidosis, acute hepatic porphyria, and primary hyperoxaluria type 1. The current investor narrative is focused on the company's transition to sustainable profitability, driven by the rapid uptake of its newer, more convenient drugs like Amvuttra, and the potential for pipeline expansion into larger markets such as cardiovascular disease, which is fueling debates about its long-term growth trajectory and valuation.…
ALNY
Alnylam Pharmaceuticals
$286.98
Investment Opinion: Should I buy ALNY Today?
Rating: Hold. The core thesis is that ALNY's powerful fundamental transition to profitability is currently overshadowed by severe technical damage and rich valuation, creating a high-risk/high-reward setup that favors waiting for a better entry point or clearer evidence of momentum stabilization.
Supporting this view, the stock trades at a reasonable forward P/E of 21.24x based on expected surging earnings, but this is juxtaposed against an extreme trailing P/E of 166.04x and a high PS ratio of 14.03x. While Q4 2025 revenue grew 84.95% YoY and the company generated $465M in TTM free cash flow, the stock has dramatically underperformed the market by -40.73% over six months. Analyst sentiment remains bullish with an average target implying significant upside, but the recent Jefferies downgrade to 'Hold' and the stock's failure to hold key technical levels introduce caution.
The thesis would upgrade to a Buy if the stock finds support above its 52-week low and reclaims the $330 resistance level on sustained volume, signaling a reversal of the downtrend, or if forward earnings estimates are revised materially higher. It would downgrade to a Sell if quarterly revenue growth decelerates below 50% or if the stock breaks decisively below the $245.96 support. At current levels, the stock appears fairly valued relative to its near-term growth prospects but remains overvalued on a trailing basis and vulnerable to further sentiment-driven declines.
Sign up to view all
ALNY 12-Month Price Forecast
The outlook for ALNY is a battle between its compelling fundamental story and its broken technical picture. The base case (50% probability) is for volatile, range-bound trading as the market digests its new status as a profitable growth company while grappling with its premium valuation. The bull case requires flawless execution and pipeline success to reignite momentum, while the bear case is a continuation of the recent derating. The stance would upgrade to bullish on a confirmed technical reversal above $330 coupled with sustained quarterly beats. It would turn bearish on a breakdown below $245, which would signal a failure of the current valuation support.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alnylam Pharmaceuticals's 12-month outlook, with a consensus price target around $373.07 and implied upside of +30.0% versus the current price.
Average Target
$373.07
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$230 - $373
Analyst target range
Analyst coverage for ALNY is active, with 9 analysts providing estimates, and the sentiment is overwhelmingly bullish, as evidenced by a series of recent 'Buy' ratings from firms like HC Wainwright, Chardan Capital, and Canaccord Genuity. The consensus is strongly positive, though one notable downgrade from Jefferies from 'Buy' to 'Hold' on March 16, 2026, introduces a note of caution amidst the prevailing optimism. The average revenue estimate for the coming period is $11.35 billion, with a wide range from $10.45 billion to $13.35 billion, indicating significant variance in growth expectations among analysts. The high end of the revenue target range implies confidence in robust commercial execution and pipeline success, while the low end may reflect concerns about competition or slower adoption, with this wide spread highlighting the inherent uncertainty in forecasting biotech commercial trajectories.
Bulls vs Bears: ALNY Investment Factors
The evidence presents a stark conflict between deteriorating price action and robust, improving fundamentals. The bear side currently has stronger near-term evidence, as the severe 35% six-month decline and broken technical picture reflect a market punishing the stock for its high valuation and perceived growth risks. However, the bull case is grounded in a powerful fundamental shift to profitability, explosive revenue growth, and strong cash generation. The single most important tension in the investment debate is whether the company's transition to sustainable profitability and pipeline expansion can justify and sustain its premium valuation multiples before negative momentum triggers a further derating. The resolution hinges on upcoming commercial execution and whether earnings growth can catch up to the lofty expectations embedded in the forward P/E of 21x.
Bullish
- Transition to Sustainable Profitability: The company swung from a net loss of $83.76 million in Q4 2024 to a net income of $186.42 million in Q4 2025, achieving a 16.99% net margin. This dramatic shift to profitability, driven by robust commercial execution, validates its business model and provides internal funding for its pipeline.
- Exceptional Revenue Growth Trajectory: Q4 2025 revenue grew 84.95% year-over-year to $1.10 billion, demonstrating the powerful uptake of its RNAi therapeutics. This growth, despite quarterly lumpiness, confirms the company's commercial leadership and the strong market demand for its innovative treatments.
- Strong Free Cash Flow Generation: The company generated $465.38 million in trailing-twelve-month free cash flow, a critical milestone for a biotech. This strong cash generation reduces reliance on external financing and provides ample resources to fund R&D for pipeline expansion into larger markets like cardiovascular disease.
- Attractive Forward Valuation: The forward P/E ratio of 21.24x is a stark discount to the trailing P/E of 166.04x, reflecting the market's expectation of a massive surge in earnings. This forward multiple is reasonable for a profitable biotech leader with high growth, especially when compared to its own historical premium valuations.
Bearish
- Severe Technical Downtrend and Weakness: The stock is down 35.07% over six months and 26.00% year-to-date, trading near 60% of its 52-week range. It has shown a -19.90% relative strength versus the S&P 500 over one month, indicating persistent and severe selling pressure and a clear breakdown in investor sentiment.
- Extremely High Trailing Valuation Multiples: A trailing P/E of 166.04x and a Price/Sales of 14.03x are extremely elevated, even for a growth biotech. This indicates the stock is priced for near-perfect execution, leaving little room for error and making it vulnerable to multiple compression on any disappointment.
- Quarterly Revenue and Earnings Volatility: Revenue declined sequentially from $1.25 billion in Q3 2025 to $1.10 billion in Q4 2025, and net income fell from $251 million to $186 million. This lumpiness highlights potential unpredictability in product sales and earnings, which can spook investors expecting smooth linear growth.
- High Financial Leverage: A debt-to-equity ratio of 1.62 indicates a leveraged capital structure. While manageable given current profitability and cash flow, this leverage increases financial risk and interest expense burden, which could pressure earnings if growth slows or rates remain elevated.
ALNY Technical Analysis
The stock is in a pronounced downtrend, having declined 35.07% over the past six months and 26.00% year-to-date as of May 1, 2026. With a current price of $296.11, it is trading at approximately 60% of its 52-week range ($245.96 to $495.55), indicating it is closer to its lows than its highs, which may signal a potential value opportunity but also reflects significant negative momentum and investor pessimism. Recent short-term momentum is also negative, with the stock down 9.92% over the past month and 12.41% over the past three months, which aligns with and reinforces the longer-term downtrend; this persistent selling pressure is further evidenced by its severe underperformance relative to the S&P 500, showing a relative strength of -19.90% over one month. Key technical support is at the 52-week low of $245.96, while resistance lies near the recent breakdown levels around $320-$330 and the 52-week high of $495.55; a decisive break below the 52-week low could trigger another leg down, whereas reclaiming the $330 level might signal a stabilization. The stock exhibits high volatility, with a maximum drawdown of -39.72% over the provided period, indicating significant risk for investors.
Beta
0.30
0.30x market volatility
Max Drawdown
-42.0%
Largest decline past year
52-Week Range
$281-$496
Price range past year
Annual Return
+1.3%
Cumulative gain past year
| Period | ALNY Return | S&P 500 |
|---|---|---|
| 1m | -13.9% | +5.6% |
| 3m | -8.7% | +8.4% |
| 6m | -36.1% | +10.0% |
| 1y | +1.3% | +25.2% |
| ytd | -28.3% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALNY Fundamental Analysis
Revenue growth is robust but shows quarterly volatility; Q4 2025 revenue was $1.10 billion, representing a massive 84.95% year-over-year growth, yet this followed a stronger Q3 with $1.25 billion in revenue, indicating some lumpiness in product sales. The growth is primarily driven by its commercial RNAi products, with segment data highlighting GIVLAARI ($160.67 million) and ONPATTRO ($70.76 million) as contributors, though the overall trajectory confirms successful commercialization. The company has achieved a significant milestone of profitability, with Q4 2025 net income of $186.42 million and a net margin of 16.99%, a dramatic improvement from a net loss of $83.76 million in Q4 2024. Gross margins remain exceptionally high at 81.77% (trailing) and were 75.60% in Q4 2025, which is typical for a successful biotech with proprietary therapeutics, though operating margins of 13.51% indicate substantial R&D and SG&A investment. The balance sheet shows a debt-to-equity ratio of 1.62, indicating a leveraged but manageable capital structure, while the current ratio of 2.76 suggests strong short-term liquidity. Critically, the company is generating substantial free cash flow, with TTM free cash flow of $465.38 million, providing internal funding for its pipeline; this is supported by a return on equity of 39.76%, signaling efficient use of shareholder capital post-profitability.
Quarterly Revenue
$1.1B
2025-12
Revenue YoY Growth
+0.84%
YoY Comparison
Gross Margin
+0.75%
Latest Quarter
Free Cash Flow
$465383000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALNY Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is extremely high at 166.04x, reflecting the market pricing recent profitability, while the forward PE is a much lower 21.24x, indicating the market expects a significant surge in earnings growth over the next year. The large gap between trailing and forward multiples underscores high growth expectations embedded in the current stock price. Compared to typical biotechnology firms, a trailing PS ratio of 14.03x and an EV/Sales of 9.63x suggest a premium valuation, justified by Alnylam's unique commercial leadership in RNAi and its path to profitability, whereas unprofitable biotechs often trade on future sales potential alone. Historically, the stock's own valuation has compressed from extreme levels; its current trailing PE of 166x is below its Q3 2025 reading of 256x (based on historical ratios data) but remains elevated compared to its more volatile past, suggesting the market is still assigning a premium for its proven platform, though not at the peak optimism seen previously.
PE
166.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -456x~71x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
92.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on valuation and earnings sustainability. The stock's extreme trailing P/E of 166x and PS of 14x make it highly susceptible to compression if quarterly earnings volatility persists or growth decelerates from the 85% YoY pace. While the company is now profitable with a 17% net margin, its debt-to-equity of 1.62 introduces financial leverage risk, and the sequential decline from Q3 to Q4 2025 in both revenue ($1.25B to $1.10B) and net income highlights earnings unpredictability that could undermine investor confidence.
Market & Competitive Risks are pronounced given the stock's severe underperformance. Trading at a 40% discount to its 52-week high, the stock exhibits high volatility with a maximum drawdown of -39.72%. Its persistent negative relative strength versus the market suggests sector rotation or a broader de-rating of growth biotechs. Competitively, while Alnylam is the RNAi leader, the commercial success of its rare disease drugs invites competition, and its expansion into larger markets like cardiovascular disease faces entrenched incumbents and high clinical development risk.
Worst-Case Scenario involves a failure to meet the high growth expectations embedded in the forward P/E of 21x, coupled with a broader market sell-off in growth stocks. A significant pipeline setback or slower-than-expected adoption of newer drugs like Amvuttra could trigger analyst downgrades and a re-rating towards its historical lows. The realistic downside is to the 52-week low of $245.96, which represents a -17% decline from the current price of $296.11. In an adverse scenario combining missed earnings and multiple compression, a drop of 25-30% is plausible, revisiting the lows seen during the stock's -39.72% maximum drawdown.
FAQ
The key risks are: 1) Valuation Compression: The extreme trailing multiples (PE 166x, PS 14x) make the stock hypersensitive to any growth disappointment, risking a sharp price decline. 2) Commercial Execution: Quarterly revenue has shown volatility (down from $1.25B in Q3 to $1.10B in Q4 2025), and sustained high growth is critical to justify the premium. 3) Financial Leverage: A debt-to-equity ratio of 1.62 increases financial risk, especially in a higher interest rate environment. 4) Pipeline & Competition: Future growth depends on successful expansion beyond rare diseases into competitive larger markets, which carries high clinical and commercial risk.
The 12-month forecast is bifurcated, with a 50% probability base case target range of $300-$380, implying modest upside from the current $296.11. This scenario assumes the company meets consensus revenue estimates of ~$11.35B and the forward P/E of ~21x holds. The bull case (30% probability) targets $400-$495, driven by superior commercial execution and pipeline success. The bear case (20% probability) sees a retest of the 52-week low near $245. The most likely outcome is the base case, where the stock consolidates after its severe decline as the market awaits evidence that explosive earnings growth can materialize to support the valuation.
The answer depends on the time horizon. On a trailing basis, ALNY is unequivocally overvalued, with a P/E of 166x and a PS ratio of 14x. However, the market is forward-looking, and the forward P/E of 21.24x suggests it is fairly valued or even slightly undervalued relative to its expected earnings surge. This massive gap indicates the market is paying a premium for future growth, not current results. Compared to many unprofitable biotechs, its valuation is justified by its profitability and cash flow. Ultimately, the stock is fairly valued for near-term expectations but carries the constant risk of derating if those expectations are not met.
ALNY presents a high-conviction, high-risk opportunity. For investors with a long-term horizon and high risk tolerance, the current price may offer an attractive entry point into the commercial leader of RNAi therapeutics, now that it is profitable and generating strong cash flow. The forward P/E of 21.24x is reasonable for its growth profile. However, given the severe 35% six-month decline and broken technicals, it is not a good buy for short-term traders or risk-averse investors. The biggest near-term risk is further multiple compression if the company stumbles on execution. A prudent strategy might be to initiate a small position and average in on further weakness.
ALNY is unequivocally a long-term investment, with a suggested minimum holding period of 3-5 years. Its value proposition is based on the multi-year commercial rollout of its RNAi platform and pipeline expansion, not short-term trading catalysts. The stock exhibits high volatility (max drawdown -39.72%) and pays no dividend, making it unsuitable for income or short-term traders. Long-term investors can potentially benefit from the company's transition to a profitable, cash-generative biotech leader, but must be prepared to endure significant price swings along the way. Short-term price action is dominated by sentiment and technicals, which are currently negative.